หุ้น PFE
- มูลค่าตลาด
- 156,176 ล้าน USD
- P/E
- 39.1
- ปริมาณซื้อขาย (วันนี้)
- 38.32M หุ้น
กราฟหุ้น PFE
ติดตามราคาหุ้น PFE ล่าสุด เพื่อให้นักลงทุนสามารถติดตามแนวโน้มราคา ติดตามสภาวะตลาด และใช้เป็นข้อมูลประกอบการวิเคราะห์ทางเทคนิคได้อย่างแม่นยำ
ข้อมูลสำคัญ
- ราคาล่าสุด
- 27.40
- ราคาเปิด
- 27.80
- สูงสุดวันนี้
- 28.11
- ต่ำสุดวันนี้
- 27.36
- มูลค่าตลาด
- 156,176 ล้าน USD
- P/E
- 39.1
- สูงสุด 52 สัปดาห์
- 31.44
- ต่ำสุด 52 สัปดาห์
- 23.62
- ปริมาณซื้อขาย (วันนี้)
- 38.32M หุ้น
ข่าวหุ้น PFE ล่าสุด
รวมข่าวและบทวิเคราะห์ล่าสุดที่เกี่ยวข้องกับ PFE จากสำนักข่าวต่างประเทศ (เปิดอ่านที่เว็บไซต์ต้นทาง)
- Better High-Yield Dividend Stock: Pfizer vs. Amcor
Key TakeawaysPfizer and Amcor both yield 6%, and Amcor raised its quarterly dividend to $0. 66 a share on Nov.
yahoo_finance · 5h ago - Why Pfizer Inc. (PFE) Could Be an Attractive Dividend and Oncology Growth Stock
We just published our list, Bruce Berkowitz’s 10 Biggest Stock Bets for 2027, and Pfizer Inc. ranked 7th on this list. Bruce Berkowitz is one of the most revered investors on Wall Street, best known for his contrarian approach and concentrated portfolio. As the founder of Fairholme Capital Management, his portfolio offers valuable insights into […]
yahoo_finance · 13h ago - Pfizer's Launched and Acquired Drugs Grew 32% in Q3 — and 3 Other Reasons to Buy the Stock Before 2027
Pfizer remains deeply unloved on Wall Street, but it is slowly turning a corner.
yahoo_finance · 1d ago - 'Very interesting': Trump suggests recent gas price drops are linked to the election
President Trump on Tuesday escalated a suggestion he has been making in recent days on social media that the recent dip in energy prices is being driven by political forces now that the midterm election is in the rearview mirror.
yahoo_finance · 1d ago - SRX Global Provides Update on Engineered T-Cell Strategy Following Pfizer–Starna Licensing Agreement
Pfizer’s $330 million upfront commitment to three pre-IND in vivo CAR-T programs highlights pharmaceutical industry interest in next-generation engineered T-cell platforms SRX’s pending acquisition of CERo Therapeutics provides exposure to CER-1236, a clinical-stage engineered T-cell therapy with seven patients dosed in the ongoing Phase 1/1b CERTAIN-T trial NORTH PALM BEACH, Fla., Nov. 20, 2026 (
yahoo_finance · 1d ago - Pfizer Inc. (PFE) Rose 20% as COVID Revenue Declined: Is Its New Product Portfolio Driving a Turnaround?
Investment management company First Pacific Advisors recently released its “FPA Queens Road Value Fund” Q3 2026 investor letter. A copy of the letter can be downloaded here. The Fund returned -1.82% in the third quarter of 2026, underperforming the S&P 500 Value Index, which gained 0.90%, while its year-to-date return reached 9.16%, slightly ahead of the […]
yahoo_finance · 1d ago
